At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 72 enrolled
Drug / intervention
Valsartan +1 moredrug
Likely dose
Valsartan 320mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Crossover Study to Assess the Effects of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension
In Brief
A Phase 2 clinical trial evaluating Valsartan and LCZ696 for Salt-sensitive Hypertension. Completed, enrolled 72 participants across 15 sites in 5 countries.
Detailed Summary
This study will evaluate the effect of LCZ696 and valsartan on natriuresis, diuresis, and blood pressure in salt-sensitive Asian hypertensive patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSalt-sensitive Hypertension
CountriesHong Kong, Singapore, South Korea, Taiwan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2012
First PostedSep 2012
Primary CompletionOct 2013
TodayJul 2026
First PostedSep 10, 2012
Enrollment StartAug 1, 2012
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 13.8 years ago
Interventions
Valsartandrug
Valsartan 320mg tablet once daily
LCZ696drug
LCZ696 400mg tablet once daily